Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord, Alan Ashworth
Science (2017) Vol. 355, Iss. 6330, pp. 1152-1158
Open Access | Times Cited: 2333

Showing 1-25 of 2333 citing articles:

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 8, pp. 753-763
Open Access | Times Cited: 1765
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Andrew N. Blackford, Stephen P. Jackson
Molecular Cell (2017) Vol. 66, Iss. 6, pp. 801-817
Open Access | Times Cited: 1606
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
DNA double-strand break repair-pathway choice in somatic mammalian cells
Ralph Scully, Arvind Panday, Rajula Elango, et al.
Nature Reviews Molecular Cell Biology (2019) Vol. 20, Iss. 11, pp. 698-714
Open Access | Times Cited: 1155
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilié, Chad Tang, Gordon B. Mills, et al.
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 81-104
Open Access | Times Cited: 967
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Theo Knijnenburg, Linghua Wang, Michael T. Zimmermann, et al.
Cell Reports (2018) Vol. 23, Iss. 1, pp. 239-254.e6
Open Access | Times Cited: 952
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 804
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt, Holly Tovey, Maggie C.U. Cheang, et al.
Nature Medicine (2018) Vol. 24, Iss. 5, pp. 628-637
Open Access | Times Cited: 768
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Oded Kopper, Chris J. de Witte, Kadi Lõhmussaar, et al.
Nature Medicine (2019) Vol. 25, Iss. 5, pp. 838-849
Closed Access | Times Cited: 656
The shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Nature (2018) Vol. 560, Iss. 7716, pp. 117-121
Open Access | Times Cited: 565
Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 563
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 722-737
Open Access | Times Cited: 537
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng Fu, Minru Liao, Rui Qin, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 499
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye‐Jung Kim, Qiwei Wang, et al.
Cell Reports (2018) Vol. 25, Iss. 11, pp. 2972-2980.e5
Open Access | Times Cited: 462
Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 446
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou, Jean–Charles Nault
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 215-229
Open Access | Times Cited: 436
DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
Rajat Gupta, Kumar Somyajit, Takeo Narita, et al.
Cell (2018) Vol. 173, Iss. 4, pp. 972-988.e23
Open Access | Times Cited: 425
Drug development in the era of precision medicine
Sarah A. Dugger, Adam Platt, David B. Goldstein
Nature Reviews Drug Discovery (2017) Vol. 17, Iss. 3, pp. 183-196
Open Access | Times Cited: 411
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 407
Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease
Tae‐In Kam, Xiaobo Mao, Hyejin Park, et al.
Science (2018) Vol. 362, Iss. 6414
Open Access | Times Cited: 387
Synthetic lethality as an engine for cancer drug target discovery
Alan Huang, Levi A. Garraway, Alan Ashworth, et al.
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 1, pp. 23-38
Closed Access | Times Cited: 385
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 380
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J. Hill, Brennan Decker, Emma A. Roberts, et al.
Cancer Discovery (2018) Vol. 8, Iss. 11, pp. 1404-1421
Open Access | Times Cited: 374
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Alan Ashworth, Christopher J. Lord
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 9, pp. 564-576
Closed Access | Times Cited: 368
Page 1 - Next Page

Scroll to top